publications-banner

Information about pipeline products

PublicationView

HER3-DXd
Other/Multi
Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima Y, Sudo K, Yoshida H, et al.
Kojima et al. Cancer Cell International (2023) 23:18 https://doi.org/10.1186/s12935-022-02844-z
HER3-DXd
Other/Multi
Quantitative analysis of drug distribution in heterogeneous tissues using dual-stacking capillary electrophoresis-mass spectrometry
Koganemaru S, Kawai T, Fuchigami H, et al.
Br J Pharmacol. 2023;180(6):762-774.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Hurvitz SA, Hegg R, Chung W-P, et al.
Lancet. 2023;401(10371):105-117.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis
Jerusalem G, Park YH, Yamashita T, et al.
Cancer Discov. 2022;12(12):2754–2762.
Edoxaban
Cardiovascular - VTE
Effect of edoxaban, F-Xa-directed oral anticoagulant on spontaneous thrombolytic activity in Apoe-/- and Ldlr-/- double knockout mice
Hyodo K, Ohta N, Ishii H, Yamashita T.
Int J Clin Cardiol. 2022;9(6):1410272.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: Exploratory cohort results in a phase II trial
Yamaguchi K, Bang YJ, Iwasa S, et al.
J Clin Oncol. 2023;41(4):816-825.
Edoxaban
Cardiovascular - AF Cardiovascular - VTE
Edoxaban in cardiovascular medicine from scientific evidence to clinical practice
Baran Budak A, Gencpinar T, Dogan E, Totan S, Akay HT.
Turk J Vasc Surg. 2022;31(3):195-206.
T-DXd
Breast Cancer
Effect of trastuzumab deruxtecan on QT/QTC interval and pharmacokinetics in HER2-positive or HER2-low metastatic/unresectable breast cancer
Shimomura A, Takano T, Takahashi S, et al.
Clin Pharmacol and Ther. 2023;113(1):160-169.
HER3-DXd
Breast Cancer Colorectal Cancer Lung Cancer
Population pharmacokinetics of patritumab deruxtecan in patients with solid tumors
Lu Y, Shimizu S, Sawamura R, et al.
J Clin Pharmacol. 2023;63(1):77-90.
Pexidartinib
Other/Multi
Pexidartinib provides modest pain relief in patients with tenosynovial giant cell tumor: Results from ENLIVEN
Healey JH, Tap WD, Gelhorn HL, et al.
Clin Orthop and Relat Res. 2023;481(1):107-116.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer